scholarly journals Relationship Between Ultrasound Features and Ki-67 Labeling Index of Soft Tissue Sarcoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Pingping Wang ◽  
Hai Li ◽  
Yu Hu ◽  
Xiaojing Peng ◽  
Xinhua Ye ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Correlation Analysis ◽  
Labeling Index ◽  
Youden Index ◽  
Vascular Density ◽  
Ki 67 ◽  
Exact Test ◽  
The Relationship ◽  
Ultrasound Features

ObjectivesTo explore the relationship between ultrasound (US) features and Ki-67 labeling index (LI) of soft tissue sarcoma (STS).MethodsForty-six patients with 47 STS lesions, between September 2014 and April 2020, were enrolled in the study. Point-biserial correlation analysis and Spearman’s correlation analysis were utilized to examining the relationship between the US features and the Ki-67 LI of STS. The differences of US features between high and low Ki-67 proliferation groups were statistically analyzed by independent t test, Wilcoxon rank-sum test, and Fisher’s exact test. The optimal cut-off points of US features revealing significant differences were estimated by the maximum Youden index.ResultsA moderate correlation between the vascular density grade and the Ki-67 LI (ρ = 0.409, P = 0.004) was found in this study. In addition, other ultrasound features were irrelevant to the Ki-67 LI. The cut-off for differentiating low- and high-proliferation groups was grade II according to the best Youden index. The area under receiver operating characteristic (ROC) curve was 0.74 (p = 0.011) with a sensitivity of 60.6% and specificity of 78.6%.ConclusionsOnly the vascular density grade of STS had a weak positive correlation with Ki-67 LI, and might be capable of predicting the proliferation of STS. Other ultrasonographic features of STS such as shape and tumor margin have no correlation with Ki-67 LI.

Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index

2019 ◽  
Vol 30 (2) ◽  
pp. 914-924 ◽  
Author(s):  
Ji Hyun Lee ◽  
Young Cheol Yoon ◽  
Sung Wook Seo ◽  
Yoon-La Choi ◽  
Hyun Su Kim
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Labeling Index ◽  
Ki 67 ◽  
Dce Mri

p53 and mdm-2 Expression in Rhabdomyosarcoma of Childhood and Adolescence: Clinicopathologic Study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study

2003 ◽  
Vol 6 (2) ◽  
pp. 128-136 ◽  
Author(s):  
Ivo Leuschner ◽  
Inken Langhans ◽  
Regina Schmitz ◽  
Dieter Harms ◽  
Adrian Mattke ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
P53 Protein ◽  
Soft Tissue Sarcomas ◽  
Response To Therapy ◽  
Mitotic Count ◽  
Childhood And Adolescence ◽  
Histological Subtype ◽  
Ki 67 ◽  
Pediatric Tumor

Rhabdomyosarcomas (RMS) are the most common malignant soft tissue sarcomas in childhood and adolescence. Despite a large number of publications about this heterogeneous group of tumors, little is known about proliferation, p53 and mdm-2 in relation to histological subtype, clinical parameter, and prognosis of patients. We studied 150 cases of RMS treated in the German Cooperative Soft Tissue Sarcoma Study (CWS) by immunohistochemistry on paraffin-embedded tissue, using antibodies against p53, mdm-2, and Ki-67. The results were correlated with histological subtype, mitotic count, and various clinical parameters. Both p53 and mdm-2 were expressed at low levels and did not show differences between embryonal and alveolar RMS. Tumors of patients with metastatic embryonal RMS showed significantly higher levels of p53 protein than nonmetastatic tumors. This might be a clue to an important role of p53 in metastatic embryonal RMS. Nevertheless, neither p53 nor mdm-2 showed any correlation to prognosis. Proliferation measured by Ki-67 immunostaining (KiS5 antibody) or mitotic count did not show significant differences between embryonal and alveolar RMS. In addition, these parameters did not correlate with response to therapy or prognosis. In conclusion, we could not demonstrate that any of the investigated parameters had an influence on prognosis of RMS. p53 protein over-expression might be a crucial step in metastatic disease for patients with embryonal RMS.

scholarly journals Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma

1999 ◽  
Vol 79 (5-6) ◽  
pp. 945-951 ◽  
Author(s):  
R L Huuhtanen ◽  
C P Blomqvist ◽  
T A Wiklund ◽  
T O Böhling ◽  
M J Virolainen ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
S Phase ◽  
Phase Fraction ◽  
Prognostic Variables ◽  
Ki 67

ATTITUDE OF CANCER PATIENTS TO TREATMENT AT SYSTEMIC THERAPY METHODS

2018 ◽  
Vol 64 (3) ◽  
pp. 429-434
Author(s):  
Valentina Chulkova ◽  
Yelena Pestereva ◽  
Taras Popov ◽  
Anatoliy Yalov ◽  
Tatyana Semiglazova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Cancer Patients ◽  
Special Kind ◽  
Emotional Reactions ◽  
Breast Cancer Patients ◽  
Treatment Groups ◽  
Need For Treatment ◽  
The Relationship

The attitude of cancer patients to treatment is a special kind of activity for overcoming the disease and its consequences. The characteristics of the attitude of cancer patients to treatment are considered: the patient’s awareness and need for information about the disease and treatment, relations with a physician in the course of treatment, emotional reactions to the disease and the need for treatment. Groups of patients with melanoma, soft tissue sarcoma and breast cancer patients with different severity of attitude to treatment were singled out. The connection between the significance of the relationship to treatment in these groups of patients with the types of attitude towards the disease and indices of viability is showed.

scholarly journals Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression

2017 ◽  
Vol 9 (04) ◽  
pp. 308-313 ◽  
Author(s):  
Madhumita Mukhopadhyay ◽  
Chhanda Das ◽  
Madhu Kumari ◽  
Ankita Sen ◽  
Bedabrata Mukhopadhyay ◽  
...  
Keyword(s):  
Labeling Index ◽  
Histological Evaluation ◽  
Proliferation Index ◽  
Ki 67 ◽  
Central Nervous System Neoplasms ◽  
Exact Test ◽  
Fisher's Exact Test ◽  
Fisher’S Exact Test ◽  
The Status ◽  
Grade Ii

Abstract BACKGROUND: Meningiomas are the most common primary central nervous system neoplasms originating from the arachnoid cap cells and constitute between 13% and 26% of all intracranial tumors. AIMS AND OBJECTIVES: The aim of the study was to analyze the age-, sex-, and site-wise distribution of different histological patterns of meningiomas seen in our center and to assess the status of estrogen receptor (ER), progesterone receptor (PR), and proliferation marker Ki-67 in various grades of meningioma. MATERIALS AND METHODS: A prospective study was done in 90 cases. Patients presented with symptoms of headache and seizure and underwent subsequent excision surgery at Neurosurgery Department were taken. We have studied histological typing and grading of the tumors, and immunohistochemical staining was done for ER, PR, and Ki-67. STATISTICAL ANALYSIS: Two-group comparison was done using Mann–Whitney U-test and Fisher’s exact test. Comparison of Ki-67 expression between Grade 1 and Grade 2 meningiomas was determined using Mann–Whitney U-test. Comparison of ER and PR status between different histological grades was done by Fisher’s exact test. Two-tailed P < 0.001 was considered statistically significant. RESULTS: According to histological type, meningothelial meningioma is most common (38.8%) followed by transitional (22.2%). PR positivity is seen in 96.34% of Grade 1 tumors, and all Grade 2 tumors were PR negative (Fisher’s exact test P < 0.001). About 3.66% of Grade 1 and all Grade 2 tumors were positive for ER (Fisher’s exact test two-tailed P < 0.001). Mean Ki-67 labeling index (LI) was 2.57 ± 1.674 among Grade I tumors, 7.11 ± 1.084 in Grade II meningiomas. CONCLUSIONS: Most of Grade 1 meningiomas show PRs positivity and lack of ERs positivity. Meningiomas with higher proliferation index and negative PR are very likely to be Grade II or Grade III. Evaluation of ER, PR status, and Ki-67 labeling index (LI) with histological evaluation helps us in providing information about the biologic behavior of meningiomas.

scholarly journals Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma

Cancer ◽  
1998 ◽  
Vol 83 (3) ◽  
pp. 490-497 ◽  
Author(s):  
Martin J. Heslin ◽  
Carlos Cordon-Cardo ◽  
Jonathan J. Lewis ◽  
James M. Woodruff ◽  
Murray F. Brennan
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Distant Metastasis ◽  
High Grade ◽  
Ki 67 ◽  
Extremity Soft Tissue Sarcoma ◽  
Mib 1

Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients

Chemotherapy ◽  
2019 ◽  
Vol 64 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Mariella Spalato Ceruso ◽  
Andrea Napolitano ◽  
Marianna Silletta ◽  
Alessandro Mazzocca ◽  
Sergio Valeri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Febrile Neutropenia ◽  
Metastatic Breast ◽  
Hematological Toxicity ◽  
Fisher Exact Test ◽  
Breast Cancer Patients ◽  
Exact Test ◽  
Dose Reductions

Background: Dexrazoxane (DEX) is indicated as a cardioprotective agent for breast cancer patients receiving the anthracycline doxorubicin. Two meta-analyses in metastatic breast cancer reported an apparent increase in the severity of myelosuppression when DEX was used. So far, no data in soft-tissue sarcoma (STS) patients are available. Methods: We retrospectively analyzed hematological toxicity data from 133 consecutive STS patients who received a chemotherapy regimen containing an anthracycline and ifosfamide (AI) in the perioperative or metastatic settings between January 2006 and December 2017. Of these, 46 received off-label DEX concurrently with the AI treatment. The differences between incidence of any of the explored outcomes were assessed according to the Fisher exact test. Results: Compared with the non-DEX group, DEX treatment was associated with significantly higher rates of grade 3/4 hematological toxicities: leukopenia (56.5 vs. 28.7%; p = 0.0014), neutropenia (69.6 vs. 24.1%; p = 0.0001), febrile neutropenia (52.2 vs. 20.7%; p = 0.0004), anemia (41.3 vs. 28.7%; p = 0.1758), and thrombocytopenia (54.3 vs. 32.1%; p = 0.0159). Similarly, in the DEX group dose reductions were more frequent compared to the non-DEX group (39.1 vs. 19.5%; p = 0.0221). Conclusion: Adding DEX to AI in STS patients leads to higher rates of bone marrow suppression in all blood components, as well as to more frequent events of febrile neutropenia and dose reductions.

Sign in / Sign up

Export Citation Format

Share Document